{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:08Z","timestamp":1786649348650,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Sickle cell anemia (SCA) is a hypercoagulable state characterized by a significant alteration in hemostatic parameters which may predispose an increased risk of vaso-occlusive crisis (VOC). Sickle cell disease (SCD) is the most common genetic disorder in sub-Saharan Africa. Nigeria bears a high disease burden with an estimated prevalence of 1%\u20133% of its population being affected by the disease. The study seeks to determine the role of von Willebrand factor (VWF), ADAMTS13, and the ratio of ADAMTS13:VWF antigen in the pathogenesis of VOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study is to evaluate the level of VWF, ADAMTS13, and their ratio in SCD subjects in Calabar and to determine their role in the pathogenesis of VOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>This is a comparative study carried out at the University of Calabar Teaching Hospital (UCTH), Calabar. Sixty SCA patients were evaluated in VOC and steady states as well as five parented healthy controls. VWF: Ag and ADAMTS13:Ag were evaluated using Assaypro enzyme-linked immunosorbent assay kits with Lot nos. 01751728 and 04222167R, respectively. Data were analyzed by IBM SPSS Chicago software version 21. The study was approved by the UCTH Institution Ethical Review Board.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean ages of the SCA subjects and controls were 23.5 \u00b1 7.2 years and 26.5 \u00b1 5.6 years, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.706). There were 23 (38.3%) males in the SCA group and 21 (42.0%) females in the controls. There was no significant difference in their sex distribution (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.063). The mean (standard deviation [SD]) of VWF in VOC, steady state, and controls were 2.52 \u00b1 0.34, 1.34 \u00b1 0.23, and 1.41 \u00b1 0.23 IU\/mL, respectively. The differences in mean were significantly higher in VOC state (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). The mean \u00b1 SD of ADAMTS13 in VOC, steady state, and controls were 0.61 \u00b1 0.10, 0.44 \u00b1 0.06, and 0.62 \u00b1 0.10 \u00b5g\/L, respectively. ADAMTS13 levels did not differ significantly across the groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.270). Similarly, there was no significant difference between ADAMTS13:VWF ratios across the groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.318).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>VWF level is elevated in VOC state and thus may be implicated in the pathogenesis of VOC. ADAMTS13 and the ratio of ADAMTS13:VWF are not significantly affected in VOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aam.aam_25_22","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T07:02:25Z","timestamp":1731049345000},"page":"124-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Determination of the Level of von Willebrand Factor, ADAMTS13, and Ratio of ADAMTS13:von Willebrand Factor in Sickle Cell Disease Patients"],"prefix":"10.4103","volume":"24","author":[{"given":"Akaba Kingsley","family":"Onorhide","sequence":"first","affiliation":[{"name":"Department of Haematology and Blood Transfusion, University of Calabar Teaching Hospital, Calabar, Cross River State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akpan Samuel","family":"Idongesit","sequence":"additional","affiliation":[{"name":"Department of Haematology and Blood Transfusion, University of Uyo, Calabar, Cross River State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osho Patrick","family":"Olanrewaju","sequence":"additional","affiliation":[{"name":"Department of Haematology, Ondo State University of Medical Sciences, Ondo City, Ondo State, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"R1-20260427","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/oxfordjournals.aje.a010288","article-title":"Sickle hemoglobin (HbS) allele and sickle cell disease: A HuGE review","volume":"151","author":"Ashley-Koch","year":"2000","journal-title":"Am J Epidemiol"},{"key":"R2-20260427","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/bmj.315.7109.656","article-title":"Management of patients with sickle cell disease","volume":"315","author":"Davies","year":"1997","journal-title":"BMJ"},{"key":"R3-20260427","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/0300-1652.129661","article-title":"Prevalence of pulmonary hypertension in sickle cell anaemia patients of a tertiary hospital in Nigeria","volume":"55","author":"Dosunmu","year":"2014","journal-title":"Niger Med J"},{"key":"R4-20260427","first-page":"262.","article-title":"Sickle cell disease screening in Northern Nigeria: The CoExistence of \u0392-thalassemia inheritance","volume":"5","author":"Inusa","year":"2015","journal-title":"Pediat Ther"},{"key":"R5-20260427","first-page":"1","article-title":"Prevalence of sickle cell disease and other haemoglobin variants in Calabar, cross river state, Nigeria","volume":"33","author":"Akaba","year":"2019","journal-title":"Annu Res Rev Biol"},{"key":"R6-20260427","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4314\/ahs.v14i2.22","article-title":"Stroke prevalence amongst sickle cell disease patients in Nigeria: A multi-centre study","volume":"14","author":"Jude","year":"2014","journal-title":"Afr Health Sci"},{"key":"R7-20260427","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trsl.2009.10.004","article-title":"Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: Implications for the coagulopathy of sickle cell disease","volume":"155","author":"Kollander","year":"2010","journal-title":"Transl Res"},{"key":"R8-20260427","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1160\/TH07-04-0279","article-title":"Von Willebrand factor: Looking back and looking forward","volume":"98","author":"Ruggeri","year":"2007","journal-title":"Thromb Haemost"},{"key":"R9-20260427","doi-asserted-by":"crossref","first-page":"e78801.","DOI":"10.1371\/journal.pone.0078801","article-title":"Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy","volume":"8","author":"Colombatti","year":"2013","journal-title":"PLoS One"},{"key":"R10-20260427","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/asheducation-2007.1.91","article-title":"Hypercoagulability in sickle cell disease: New approaches to an old problem","author":"Ataga","year":"2007","journal-title":"Hematology"},{"key":"R11-20260427","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.20653","article-title":"ADAMTS13 activity in sickle cell disease","volume":"81","author":"Schnog","year":"2006","journal-title":"Am J Hematol"},{"key":"R12-20260427","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/jth.13728","article-title":"Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state","volume":"15","author":"Sins","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R13-20260427","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11239-016-1418-4","article-title":"Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait","volume":"43","author":"Al-Awadhi","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"R14-20260427","doi-asserted-by":"crossref","first-page":"3235.","DOI":"10.1182\/blood.V120.21.3235.3235","article-title":"Severe sickle cell disease is characterised by how ADAMTS 13\/VWF: Ag ratio","volume":"120","author":"Despoina","year":"2012","journal-title":"Blood"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_25_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:51Z","timestamp":1786647171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_25_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_25_22","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"2022-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}